CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study

Keunchil Park, Eun Kyung Cho, Maximino Bello, Myung-Ju Ahn, Sumitra Thongprasert, Eun-Kee Song, Victoria Soldatenkova, Henrik Depenbrock, Tarun Puri, Mauro Orlando

Cancer Research and Treatment. 2017;49(4):937-946. Published online 2017 January 6 DOI: https://doi.org/10.4143/crt.2016.423

Keunchil Park, Eun Kyung Cho, Maximino Bello, Myung-Ju Ahn, Sumitra Thongprasert, Eun-Kee Song, Victoria Soldatenkova, Henrik Depenbrock, Tarun Puri, Mauro Orlando

Cancer Research and Treatment. 2017;49(4):937-946

Link1

Link2 Link3

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer

L. Paz-Ares, M.A. Socinski, J. Shahidi, R.R. Hozak, V. Soldatenkova, R. Kurek, M. Varella-Garcia, N. Thatcher, F.R. Hirsch

Annals of Oncology. 2016;27(8):1573-1579

Link1 Link2 Link3

Subgroup Analysis of Elderly Patients in Squire: a Randomized, Multicenter, Open-Label, Phase Iii Study of Necitumumab (N) Plus Gemcitabine-Cisplatin (GC) Chemotherapy Versus Gc Alone in First-Line Treatment of Patients (PTS) with Stage Iv Squamous Non-Small Cell Lung Cancer (SQ-NSCLC)

N. Thatcher, T.-E. Ciuleanu, R. Ramlau, C. Schumann, L. Paz-Ares, H. Depenbrock, S. Nanda, N. Chouaki, M. Socinski

Annals of Oncology. 2015;26:i29

Link1 Link2 Link3

1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)

L. Paz-Ares, M.A. Socinski, J. Shahidi, R.R. Hozak, V. Soldatenkova, N. Thatcher, F. Hirsch

Journal of Thoracic Oncology. 2016;11(4):S153

Link1 Link2

Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)

Martin Reck, Michael Thomas, Cornelia Kropf-Sanchen, Jörg Mezger, Mark A. Socinski, Henrik Depenbrock, Victoria Soldatenkova, Jacqueline Brown, Thomas Krause, Nick Thatcher

Oncology Research and Treatment. 2016;39(9):539-547

Link1 Link2

Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer

N. Mylonakis, A. Athanasiou, N. Ziras, J. Angel, A. Rapti, S. Lampaki, N. Politis, C. Karanikas, C. Kosmas

Lung Cancer. 2010;68(2):240-247

Link1 Link2

Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB–IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale

V Gebbia

Lung Cancer. 2003;39(2):179-189

Link1 Link2

P382 A randomized phase II trial of sequential gemcitabine plusvinorelbine followed by gemcitabine plus Ifosfamide versus gemcitabine plus cisplatin in the treatment of chemonaïve patients with stage III and IV non-small cell lung cancer (NSCLC)

G. Teodorescu, T. Ciuleanu, A. Grigorescu, E. Firoiu, D. Ruta Muresan

Lung Cancer. 2005;49:S271

Link1 Link2

Corrigendum to “Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan” [Lung Cancer, 129 (March) (2019) 55–62]

Satoshi Watanabe, Hiroshige Yoshioka, Hiroshi Sakai, Katsuyuki Hotta, Mitsuhiro Takenoyama, Kazuhiko Yamada, Shunichi Sugawara, Yuichi Takiguchi, Yukio Hosomi, Keisuke Tomii, Seiji Niho, Nobuyuki Yamamoto, Makoto Nishio, Yuichiro Ohe, Terufumi Kato, Toshiaki Takahashi, Ami Kamada, Kazumi Suzukawa, Yukie Omori, Sotaro Enatsu, Kazuhiko Nakagawa, Tomohide Tamura

Lung Cancer. 2019;132:157-158

Link1 Link2

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan

Lung Cancer. 2019;129:55-62

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.